Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 5/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.56 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31612490 | 0.94 | SIGMAR1 (0.55) | TMEM97SIGMAR1PYCR1KCNH2KDM4E | |
| SCHEMBL7132148 | 0.90 | MAPT (0.53) | TMEM97SIGMAR1PYCR1KCNH2KDM4E | |
| SCHEMBL14006726 | 0.88 | PYCR1 (0.56) | TMEM97SIGMAR1PYCR1KDM4ETSHR | |
| SCHEMBL8254170 | 0.84 | KDM4E (0.50) | TMEM97SIGMAR1PYCR1KCNH2KDM4E | |
| SCHEMBL7128368 | 0.84 | SIGMAR1 (0.55) | TMEM97SIGMAR1PYCR1KCNH2KDM4E | |
| SCHEMBL12082322 | 0.82 | PYCR1 (0.52) | TMEM97SIGMAR1PYCR1KCNH2KDM4E | |
| SCHEMBL9129256 | 0.82 | KCNH2 (0.62) | KCNH2MAPT | |
| SCHEMBL8722902 | 0.82 | SIGMAR1 (0.58) | TMEM97SIGMAR1KCNH2KDM4EMAPT | |
| SCHEMBL7764937 | 0.82 | SIGMAR1 (0.58) | TMEM97SIGMAR1KCNH2KDM4EMAPT | |
| SCHEMBL8724611 | 0.82 | SIGMAR1 (0.58) | TMEM97SIGMAR1KCNH2KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0407032-B1 | Aromatic and heteroaromatic amines for treating depressions, cerebral insufficiency disorders or dementia | WYETH JOHN & BROTHER LTD (GB) | 1994-11-09 | — | — | EP | claimed |
| US-5086073-A | Brain disorders | JOHN WYETH & BROTHER LIMITED (GB) | 1992-02-04 | — | — | US | claimed |
| EP-0407032-A2 | Aromatic and heteroaromatic amines for treating depressions, cerebral insufficiency disorders or dementia | JOHN WYETH & BROTHER LIMITED (GB) | 1991-01-09 | — | — | EP | claimed |
| US-9447122-B2 | Arginase inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2016-09-20 | — | — | US | disclosed |
| US-9346795-B2 | Substituted sulfonamides useful as antiapoptotic Bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-24 | — | — | US | disclosed |
| US-8894970-B2 | Arginase inhibitors and methods of use thereof | CORRIDOR PHARMACEUTICALS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-15 | — | — | US | disclosed |
| WO-2012162365-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-29 | — | — | WO | disclosed |
| US-20120171116-A1 | Arginase Inhibitors and Methods of Use Thereof | CORRIDOR PHARMACEUTICALS, INC. | 2012-07-05 | — | — | US | disclosed |
| US-5422355-A | Also for treating memory impairment, dementia or cerebral insufficiency | JOHN WYETH & BROTHER, LIMITED (GB) | 1995-06-06 | — | — | US | disclosed |
| EP-0407032-B1 | Aromatic and heteroaromatic amines for treating depressions, cerebral insufficiency disorders or dementia | WYETH JOHN & BROTHER LTD (GB) | 1994-11-09 | — | — | EP | disclosed |
| US-5260331-A | Selective gamma aminobutyric acid autoreceptors; treatment of dementia | JOHN WYETH & BROTHER LIMITED (GB) | 1993-11-09 | — | — | US | disclosed |
| US-5086073-A | Brain disorders | JOHN WYETH & BROTHER LIMITED (GB) | 1992-02-04 | — | — | US | disclosed |
| EP-0407032-A2 | Aromatic and heteroaromatic amines for treating depressions, cerebral insufficiency disorders or dementia | JOHN WYETH & BROTHER LIMITED (GB) | 1991-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120171116-A1 | Arginase Inhibitors and Methods of Use Thereof | ARG1, ARG2, PRMT1 | TMEM97 4171/4885SIGMAR1 2341/4885PYCR1 418/4885 |
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BCL2, BAX, BCL2A1 | TMEM97 1315/4885SIGMAR1 2792/4885PYCR1 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.